Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nuvation Bio
Biotech
Nuvation cancels plans to directly challenge Servier's Voranigo
Nuvation’s plans for its brain-penetrant mIDH1 inhibitor, called safusidenib, had involved a head-to-head study against Voranigo.
James Waldron
Nov 4, 2025 7:10am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
Nuvation halts BET inhibitor after considering phase 1 data
Aug 5, 2024 11:02am
John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders
Mar 29, 2024 9:30am
Nuvation drops tumor asset and reduces staff by a third
Aug 1, 2022 9:35am
Roche taps new CEO—Chutes & Ladders
Jul 22, 2022 9:30am
